Cargando…
Efficacy of Postnatal In Vivo Nonsense Suppression Therapy in a Pax6 Mouse Model of Aniridia
Nonsense mutations leading to premature stop codons are common occurring in approximately 12% of all human genetic diseases. Thus, pharmacological nonsense mutation suppression strategies would be beneficial to a large number of patients if the drugs could be targeted to the affected tissues at the...
Autores principales: | Wang, Xia, Gregory-Evans, Kevin, Wasan, Kishor M., Sivak, Olena, Shan, Xianghong, Gregory-Evans, Cheryl Y. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5440746/ https://www.ncbi.nlm.nih.gov/pubmed/28624217 http://dx.doi.org/10.1016/j.omtn.2017.05.002 |
Ejemplares similares
-
A nonsense PAX6 mutation in a family with congenital aniridia
por: Han, Kyoung Hee, et al.
Publicado: (2016) -
Nonsense suppression induced readthrough of a novel PAX6 mutation in patient‐derived cells of congenital aniridia
por: Liu, Xiaoliang, et al.
Publicado: (2020) -
Restoration of functional PAX6 in aniridia patient iPSC-derived ocular tissue models using repurposed nonsense suppression drugs
por: Lima Cunha, Dulce, et al.
Publicado: (2023) -
PAX6 disease models for aniridia
por: Abdolkarimi, Dorsa, et al.
Publicado: (2022) -
PAX6 aniridia and interhemispheric brain anomalies
por: Abouzeid, Hana, et al.
Publicado: (2009)